Therapeutics & Diagnostics
Diagnostic, Prognostic, Therapeutic and Patient Stratification Tools for Cancers
Therapeutics for the most common & fatal type of brain cancer
- The molecular mechanism of treatment resistance in glioblastoma now revealed as overexpression of PP2A inhibitor PME-1 (Kaur et al., Cancer Res, Epub 2016)
- Efficient therapy is accomplished by combining the blocking of PME-1 and/or HDAC4 with chemotherapy
- Significant evidence in a xenograft mouse model
- WO2014009609A1, EP2872631B1; WO2014033367A1, EP2890986B1; WO2012175798A2, EP2723450B1, JP6001655B2, US9476050B2
![Glioblastoma PME-1, HDAC4](/sites/default/files/inline-images/glioblastoma.png)
PME-1, HDAC4
Prognostic gene variants in aggressive prostate cancer
- Genetic predisposition to aggressive PrCa in Caucasians now traced to two synergistic germline mutations (ms submitted)
- Dual carriers of the two gene variants have a high risk of developing clinically relevant prostate cancer (OR 23.4) and especially aggressive PrCa such as CRPC (OR 36.6).
- Provides a new tool for patient stratification and for improved personalized care with more informed therapeutic actions
- WO2017203100A1
![Prostate Cancer Gene variants](/sites/default/files/inline-images/prostate-cancer.png)
Gene variants
Immunostimulatory glycocluster compounds for immunotherapy of cancers
- Used in monotherapy or as adjuvants to stimulate immune response towards malignant cells
- Significantly suppressed thegrowth of melanoma in a xenograft mouse model
- WO2012175813A1; WO2017109288A1; WO2017207542A1
![Melanoma Immuno-oncologic treatment](/sites/default/files/inline-images/melanoma.png)
Immuno-oncologic treatment
Prognostic expression markers for Acute Myeloid Leukemia (AML)
- Two new biomarkers:
- A novel oncogene variant predicting poor survival in AML (HR 1.51)
- A cell signaling protein predicting relapse after chemotherapy (HR 3.7)
- Facilitate stratification of patients with poorest prognosis for the most efficient therapies
- Independent of current risk grouping – provide significant added value for personalized therapy
- Priority patent application FI20176032 (public 05/2019)
![Solid cancers Prognostics & Therapy](/sites/default/files/inline-images/solid-cancer.png)
Prognostics & Therapy
Novel immuno‐oncological approach
Efficient elimination of the tumor cell-derived immunosuppressant adenosine
- Invention directly combinable with therapeutic antibodies (e.g. anti-CD73 / anti-CD39)
- Targets aggressive cancers such as melanoma
- Efficacy studies in mouse cancer models (ongoing)
- Priority patent application public 07/2019
![Acute Myeloid Leukemia Personalized treatment](/sites/default/files/inline-images/acute-leukemia.png)
Personalized treatment